Most medtech founders can describe the moment. The prototype works on the bench, investors like the demo, and a pilot clinic is ready to try it. Then a usability study shows nurses misreading the display, the regulatory consultant finds gaps in the design history file, and the contract manufacturer says the enclosure cannot be produced at the planned cost. The device goes back to the drawing board.

Call it the redesign tax. It rarely appears in a business plan, yet it is one of the most common reasons medical device programmes run over budget and miss launch windows. And unlike many startup risks, it is largely avoidable.

Where the Redesign Tax Comes From

Late-stage redesigns usually trace back to three decisions that were postponed rather than made.

Usability is tested too late

Regulators in both the EU and the US expect manufacturers to show that intended users can operate a device safely. Under IEC 62366 and FDA human factors guidance, that means formative testing during development and a summative validation study before submission. Teams that skip early formative work often discover use errors only in the final study, when the design is frozen and changes are expensive. A confusing alarm or an awkward grip is a small fix in month three and a serious setback in month eighteen.

Compliance is treated as paperwork

Many startups build first and document later, planning to assemble the technical file once the product works. But design controls, risk management under ISO 14971, and traceability between requirements and tests cannot be convincingly reconstructed after the fact. When the documentation reveals that a risk was never properly analysed, the fix is often a design change, not a paragraph.

Manufacturing is an afterthought

A prototype printed in a lab is not a product. Material choices affect biocompatibility testing, tolerances affect yield, and assembly steps affect unit cost. Changing a material late can trigger new biocompatibility work, and redesigning for an injection-moulding process can ripple through electronics and mechanical layouts.

Why This Is a Business Problem, Not Just an Engineering One

For a venture-backed medtech company, time is runway. A six-month redesign can mean an extra funding round on weaker terms, a missed clinical partnership, or a competitor reaching the market first.

It also affects the commercial case. Hospitals and clinics are B2B buyers with procurement committees, and they increasingly assess how a device fits clinical workflows, how much training staff need, and how often it will fail in daily use. A device that passed regulatory review but frustrates nurses will struggle in tenders and generate support costs long after launch.

Investors understand this. In due diligence, a well-structured design history file, a living risk management file, and evidence of early user testing signal that a team can reach approval on a predictable timeline.

What Well-Run Medtech Programmes Do Differently

Teams that avoid the redesign tax tend to share a few habits:

• They involve real users from the start. Clinicians, patients, and caregivers are observed in their actual environments before requirements are fixed.
• They build the risk file alongside the design. Hazards are identified and mitigated as decisions are made, not catalogued at the end.
• They use prototypes to answer questions. Each prototype tests a specific assumption about usability, function, or manufacturability, rather than simply showing progress.
• They design for manufacturing early. Suppliers and production methods are considered during concept development.
• They choose regulatory pathways early. Whether the target is EU MDR, FDA 510(k), De Novo, or both markets, the pathway shapes testing, documentation, and timelines from day one.

None of this slows development. It moves effort earlier, where changes are cheap, and removes it from the end, where they are not.

Choosing the Right Development Partner

Few early-stage companies have human factors specialists, mechanical and electronics engineers, regulatory experts, and manufacturing know-how under one roof. Many therefore work with an external development partner, and that choice has a direct effect on the size of the redesign tax.

The criteria worth checking are practical. Is the partner certified to ISO 13485? Does it run human factors engineering in-house rather than subcontracting it? Has it taken devices through the regulatory pathway you need? Can it support the move from prototype to pilot production?

Pilotfish, a medical device design firm with offices in Berlin, Amsterdam, Lisbon, and Taipei, is one example of this integrated model. Its teams combine human factors, hardware engineering, risk management, and regulatory documentation within an ISO 13485-certified process, and its medtech work includes an at-home cough monitoring device for Carepath Technologies and the TipTraQ sleep diagnostic system developed with Pranaq. Whichever partner a company chooses, the principle is the same: usability, engineering, and compliance should be handled together rather than handed from one specialist to the next.

The Takeaway

Medical device development will never be fast or cheap. But much of its cost comes from rework, and most of that rework is predictable. Founders who treat usability, compliance, and manufacturing as design inputs from the first sketch protect their runway, strengthen their position with investors, and give hospital buyers a product that works the way clinicians actually work.